Which weight loss injection works the fastest — and what does that actually mean?

Step 1: Understand what 'fastest' means in practice (and why it matters

A question our prescribers hear most weeks goes something like this: "I've read online that one injection is quicker) can I just start on that one?" It's a fair question. The honest answer is that speed in weight management means the rate at which body weight reduces over months, not days, and that rate is shaped by which medicine you take, the dose you reach, how your body responds, and what else you do alongside it.

Both licensed injections (tirzepatide and semaglutide) work by mimicking gut hormones released after eating. They slow the rate at which the stomach empties, reduce appetite, and improve the signals that tell your brain you've had enough. Neither is an immediate intervention. Treatment starts at a low dose that your system adjusts to, then moves upward on a schedule set by the prescriber. The first few weeks are about tolerability, not maximum effect.

So when people ask about the fastest weight loss injections, the evidence-based answer requires looking at full trial durations (68 to 72 weeks) rather than early results. That framing shapes everything that follows.

Step 2: Compare the two licensed options on the evidence available

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist made by Eli Lilly. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking the 15mg dose lost an average of around 20–21% of body weight over 72 weeks. That figure places it ahead of every other single licensed weight-management injection tested over a comparable period.

Semaglutide (Wegovy) is a GLP-1 receptor agonist made by Novo Nordisk. The STEP 1 trial showed an average reduction of roughly 15% over 68 weeks at the 2.4mg maintenance dose. A higher 7.2mg dose was approved by the MHRA in early 2026, with trial data reporting around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide considerably.

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, put the two medicines directly against each other in adults with obesity but without type 2 diabetes. Tirzepatide produced the greater average reduction. NICE's appraisal of tirzepatide (TA1026) also notes that indirect comparisons favour tirzepatide, while acknowledging the evidence base continues to grow. Both medicines carry NICE recommendations and both are available in the UK on private prescription through regulated pharmacies.

For a broader look at which injection works fastest across different patient profiles, the comparison is more nuanced than any single trial can settle.

Step 3: Recognise that individual factors shape your result more than brand choice

Trial averages describe populations, not individuals. Someone who tolerates dose increases well, maintains consistent protein intake, stays active, and uses their injection on the same day each week will typically see better results than someone who struggles with side effects at higher doses and pauses treatment repeatedly. These variables matter as much as which medicine appears faster in a pooled analysis.

The most common side effects of both injections are gastrointestinal: nausea, loose stools, constipation, and indigestion tend to be most noticeable after a dose step-up, then ease over days to a couple of weeks for most people. Starting low and titrating slowly is how the licensed schedules are designed, it protects tolerability, which in turn protects long-term results. The NHS medicines page for tirzepatide covers the full side-effect profile in plain language.

There are also clinical considerations that affect which medicine a prescriber chooses. Certain conditions, current medications, and personal circumstances all feed into that decision. Someone already on oral contraceptives, for instance, needs specific advice about pill absorption during the first weeks of tirzepatide treatment and after each dose increase. These are the kinds of details that only emerge through a proper clinical assessment, not a checklist.

If you want to understand the practical realities of fast-acting injections before committing to a path, that context is worth reading alongside the trial data.

Step 4: Know what the clinical process looks like before you start

Both Mounjaro and Wegovy are prescription-only medicines. The legal route to either is a clinical assessment by a qualified prescriber, who reviews your health history, current medicines, BMI, and any relevant conditions before deciding whether treatment is appropriate and, if so, which one. There is no shortcut that keeps you safe.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the same day it's submitted. Identity is verified, weight is confirmed on a live video call, and treatment is dispatched the same day if clinically approved, arriving free the next working day via DPD, in plain packaging.

The full picture of what these injections are covers mechanism, eligibility, and what to expect in more detail, and if you are weighing up your options before starting, our guide to the fastest working weight loss injections explains how speed is measured and what the clinical evidence actually shows. And if cost is on your mind, our treatment page sets out exactly what's included in a single transparent price, with no subscription and no hidden fees. Speed matters, but so does doing this properly.